These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27595988)

  • 1. Periocular discoloration after using a prostaglandin analog for eyelash enhancement: evaluation with reflectance confocal microscopy.
    N Horváth O; Letulé V; Ruzicka T; Herzinger T; Goldscheider I; von Braunmühl T
    J Cosmet Dermatol; 2017 Mar; 16(1):18-20. PubMed ID: 27595988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy.
    Sharpe ED; Reynolds AC; Skuta GL; Jenkins JN; Stewart WC
    Curr Eye Res; 2007 Dec; 32(12):1037-43. PubMed ID: 18085467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latisse-induced periocular skin hyperpigmentation.
    Priluck JC; Fu S
    Arch Ophthalmol; 2010 Jun; 128(6):792-3. PubMed ID: 20547960
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
    Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
    Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periocular skin hyperpigmentation in children treated with prostaglandin analogues.
    Al-Zobidi M; Khandekar R; Craven ER; Hanafi S; Edward DP
    J AAPOS; 2015 Feb; 19(1):49-53. PubMed ID: 25727587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice.
    Esaki Y; Katsuta O; Kamio H; Noto T; Mano H; Iwamura R; Yoneda K; Odani-Kawabata N; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):529-533. PubMed ID: 32412835
    [No Abstract]   [Full Text] [Related]  

  • 7. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.
    Giannico AT; Lima L; Russ HH; Montiani-Ferreira F
    J Ocul Pharmacol Ther; 2013 Nov; 29(9):817-20. PubMed ID: 23981234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases.
    Yoshino T; Fukuchi T; Togano T; Seki M; Ikegaki H; Abe H
    Jpn J Ophthalmol; 2013 Mar; 57(2):172-8. PubMed ID: 23208023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis.
    Yoelin SG; Fagien S; Cox SE; Davis PG; Campo A; Caulkins CA; Gallagher CJ
    Dermatol Surg; 2014 Oct; 40(10):1118-24. PubMed ID: 25229783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat and Volume Loss?
    Jamison A; Okafor L; Ullrich K; Schiedler V; Malhotra R
    Aesthet Surg J; 2022 Oct; 42(11):1241-1249. PubMed ID: 35700523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minocycline hyperpigmentation: skin, tooth, nail, and bone involvement.
    Wolfe ID; Reichmister J
    Cutis; 1984 May; 33(5):457-8. PubMed ID: 6478869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.
    Steinsapir KD; Steinsapir SMG
    Dermatol Surg; 2021 May; 47(5):658-665. PubMed ID: 33625141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A delayed side effect of topical thiotepa.
    Hornblass A; Adler RI; Vukcevich WM; Gombos GM
    Ann Ophthalmol; 1974 Nov; 6(11):1155-7. PubMed ID: 4215360
    [No Abstract]   [Full Text] [Related]  

  • 14. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
    McCarey BE; Kapik BM; Kane FE;
    Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hypotrichosis of the eyelashes: focus on bimatoprost.
    Fagien S
    Plast Surg Nurs; 2015; 35(2):82-91. PubMed ID: 26020474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periocular mexametric melanin and erythema indexes in adult glaucoma patients treated with topical prostaglandin analogs.
    Duman N; Duman R; Yavaş GF; Doğruk Kaçar S; Özuğuz P; Çetinkaya E
    Cutan Ocul Toxicol; 2017 Mar; 36(1):9-11. PubMed ID: 26911512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical bimatoprost 0.03% and iatrogenic eyelid and orbital lipodystrophy.
    Sira M; Verity DH; Malhotra R
    Aesthet Surg J; 2012 Sep; 32(7):822-4. PubMed ID: 22942109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
    Celik T; Kosker M
    Cont Lens Anterior Eye; 2015 Feb; 38(1):59-60. PubMed ID: 25249292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iris heterochromia and unilateral eyelash hypertrichosis.
    Rao RC; Ballard TN; Chen TC
    JAMA; 2015 May; 313(19):1967-8. PubMed ID: 25988467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.
    Smith S; Fagien S; Whitcup SM; Ledon F; Somogyi C; Weng E; Beddingfield FC
    J Am Acad Dermatol; 2012 May; 66(5):801-6. PubMed ID: 21899919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.